瑞舒伐他汀联合恩替卡韦治疗慢性乙型肝炎合并脂肪肝的疗效观察

Therapeutic effect of rosuvastain combined with entecavir in the treatment of chronic hepatitis B complicated with fatty liver

目的观察瑞舒伐他汀联合恩替卡韦治疗慢性乙型肝炎合并脂肪肝的疗效。方法入选58例慢性乙型肝炎合并脂肪肝的患者随机分为治疗组（30例）和对照组（28例）。对照组给予恩替卡韦治疗48周,治疗组相同给予恩替卡韦治疗的情况下,在第12-24周每晚加服瑞舒伐他汀联合治疗。两组均给予基础对症支持治疗,疗程为48周。在治疗前、治疗后的各个时间点检测血清ALT水平、HBV-DNA、甘油三酯（TG）、总胆固醇（TC）、LDL-C、HDL-C进行比较。结果两组肝功能指标、HBVDNA、血清ALT水平均有改善,其中治疗组的血清ALT水平、TC、TG、LDL-C、HDL-C的改善明显优于对照组（P〈0.05）。结论瑞舒伐他汀联合恩替卡韦治疗慢性乙型肝炎合并脂肪肝的患者在血清ALT水平改善上有明显效果,对于脂肪肝疗效显著,且不良反应少。

Objective To study the therapeutic efficacy of rosuvastain combined with entecavir for treating patients of chronic hepatitis B （CHB） complicated with fatty liver. Methods Fifty-eight patients of chronic hepatitis B complicated with fatty liver were randomly assigned into two groups. The control group （n=28） was treated by entecavir for 48 weeks, and the study group （n=30） applied rosuvastatin every night from the 12th to 24th week based on the control group. The serum ALT, HBV-DNA, TG, TC, LDL-C, and HDL-C of the patients before and after treatment were compared. Results The indices of liver function, HBV-DNA, serum ALT of the two group were improved significantly （P〈0.05）, and the improvement of serum ALT, TG, TC, LDLC, HDL-C of the study group was significantly better than that of the study group （P〈0.05）. Conclusion For treating patients of chronic hepatitis B complicated with fatty liver, rosuvastain combined with entecavir has significant effect in improving serum ALT, with fewer side effects.